AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01657877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium monoflurophosphate
Description: 500 to 1500 parts per million (ppm) of fluoride
Study NCT01657877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium monoflurophosphate
Description: 500 to 1500 parts per million (ppm) of fluoride
Study NCT01657877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No CSP and no fluoride
Study NCT01089309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Spironolactone orally, at a dose of 50 mg/day for 12 months
Study NCT04191876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wellth - Financial Incentives
Description: Patients who are willing to participate will be offered financial incentives for medication adherence through an app (Wellth) over 10 weeks.
Study NCT03304756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAP
Description: cisplatin (50 mg/m2) in combination with doxorubicin (50 mg/m2) and cyclophosphamide (500 mg/m2) every 21 days and for a total of 6 cycles
Study NCT01135082 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: valent pneumococcal conjugated vaccine
Description: Dosage: 0.5 ml per dose Administration: intramuscular injection Location: left deltoid area x 1 injection Frequency: depend on first dose of vaccination. If 2-6 months of age, vaccination at month 0, 2, and 4. If 7-23 months of age, vaccination at month 0 and 2. If 2-9 years of age, vaccination at month 0. If patient is HIV positive, vacciation months 0 and 2 if age is 2-9 years.
Study NCT01648595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: In case group, 50 micrograms fentanyl was prescribed in two doses with an interval of 1 hour after being diluted in 4 cc normal saline
Study NCT00900783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valacyclovir
Description: 1 gram, three times a day for seven days
Study NCT00900783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FV-100
Description: 400 mg, once daily, for seven days
Study NCT00900783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FV-100
Description: 200 mg, once daily, for seven days
Study NCT00900783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir placebo
Description: three times a day, for seven days
Study NCT00900783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FV-100 placebo
Description: once daily, for seven days
Study NCT00784147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibalizumab
Description: Ibalizumab 800 mg IV every 2 weeks
Study NCT00784147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibalizumab
Description: Ibalizumab 2000 mg IV every 4 weeks
Study NCT03131349 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum zinc and iron
Description: history ,examination,investigations
Study NCT00480155 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Frozen FluMist®
Description: Monovalent vaccine is supplied in intranasal sprayers containing 0.5 mL.
Study NCT00480155 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01972945 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginoscopy
Description: Vaginoscopy, otherwise known as the 'no touch' technique, describes a technique where the hysteroscope is guided into the uterus without the need for potentially painful vaginal instrumentation i.e. passage of a vaginal speculum to separate the vaginal walls, cleansing of the cervix and sometimes application of traumatic forceps to the ectocervix in order to stabilise it.
Study NCT01972945 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Hysteroscopy
Description: Traditional hysteroscopy consists of introducing speculum and grasping of the cervix to provide counter traction to allow instrumentation of the uterus. Introducing a speculum also allows the cervix to be cleaned with sterilising fluid.
Study NCT00329563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Up to 2 liter infusion of cold 4 degree C normal saline
Description: Patients randomized to field cooling will receive up to 2 liters of 4oC normal saline. Control patients will receive standard of care following resuscitation.
Study NCT04718233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 25Mg Tablet
Description: Sildenafil citrate at a dose of 25mg will be administered orally in patients with recurrent pregnancy loss
Study NCT04718233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo will be administered orally in patients with recurrent pregnancy loss
Study NCT03171935 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula Oxygenation
Description: High-flow nasal cannula oxygenation will be applied immediately after early extubation, with a gas flow rate of 50 liters per minute and a fraction of inspired oxygen of 1.0 at initiation. The fraction of inspired oxygen will be subsequently adjusted to maintain a peripheral oxygen saturation of 92% or more.
Study NCT03171935 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive Positive Pressure Ventilation
Description: Noninvasive positive pressure ventilation will be applied immediately after early extubation, with a noninvasive ventilator (Respironics V60, Philips) using the NIPSV mode at initiation. The fraction of inspired oxygen will be adjusted to achieve SpO2 >92% with an initial expiratory positive airway pressure (EPAP) of 4 cmH2O. EPAP will be increased gradually in increments of 1-2 cmH2O, up to a maximum of 12 cmH2O, to achieve SpO2 >96%. Inspiratory positive airway pressure (IPAP) will be initially set at 8 cmH2O and be increased gradually in increments of 1-2 cmH2O according to patients' tolerance to obtain a tidal volume (VT) of 6-8 mL/kg.
Study NCT03171935 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional weaning
Description: The patients will undergo conventional weaning protocol. Extubation and subsequent oxygen therapy with venturi mask will be performed after successful spontaneous trial.
Study NCT03094962 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Motion capture
Description: Capture kinematics of finger movements
Study NCT03094962 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MR scan
Description: Capture MR images of hand and fingers in three postures
Study NCT03094962 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT scan
Description: Capture CT images of hand and fingers in three postures
Study NCT02725567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Granules in sachet for oral administration.
Study NCT01585298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTY720
Study NCT02929719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test.
Description: gel
Study NCT02929719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aczone Gel 5%
Description: gel
Study NCT02929719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: gel
Study NCT01539408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: single dose of 400 mcg misoprostol administered sublingually
Study NCT01539408 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery Manual vacuum aspiration (MVA)
Description: standard surgical treatment
Study NCT00680147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief informational intervention to promote HPV vaccine acceptance
Description: Teen and parent participants will receive a brief informational intervention that provides basic facts about the HPV vaccine, including the health benefits and three-dose requirements, along with information regarding where to go to receive the vaccination. A coupon for a free HPV vaccination will provided to the parent for use by their teenage daughter.
Study NCT04263805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vignette with emphasis on research climate
Description: A vignette describing a dilemma situation for a researcher (e.g. adding an honorary author) with or without a research environment factor (i.e. an environment where other researchers commit detrimental research practice)
Study NCT04263805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vignette with emphasis on research climate
Description: A vignette describing a dilemma situation for a researcher (e.g. adding an honorary author) with or without a research environment factor (i.e. an environment where other researchers commit detrimental research practice)
Study NCT02987998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (50mg/m2 IV D1, 8, 29, 36)
Study NCT02987998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide (50mg/m2 IV D1-5, 29-33)
Study NCT02987998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (200mg IV D1, 21, 42)
Study NCT02987998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation (1.8Gy/D to 45Gy in 25 fractions)
Study NCT01154270 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: carbon ion boost
Description: 8 fractions carbon ion (8 x 3 GyE C12) therapy followed by 25 fractions of IMRT corresponding to a total dose of approximately 74 GyE. Treatment duration is approximately 61/2-7 weeks
Study NCT03599336 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Reverse Total Shoulder Arthroplasty (rTSA)
Description: Surgical management will include placement of fracture specific, cemented reverse total shoulder arthroplasty components as per standard surgical care and routine postoperative rehabilitation.
Study NCT03599336 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nonoperative Treatment
Description: Subjects allocated to the nonoperative treatment arm will maintain sling immobilization for 3 weeks. The sling will be removed for elbow, wrist and hand range of motion (ROM), hygiene, and dressing only. At 3 weeks passive ROM in external rotation (ER) and forward elevation (FE) will be added. At 6 weeks from injury, the sling will be removed and stretching in all planes will be allowed. Use of the arm will be up to a fork/knife/toothbrush only. At 3 months from injury, strengthening will be added. Supervised physical therapy will be offered to patients for use at their discretion, as is current practice.
Study NCT02749136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preoperative modified FOLFIRINOX and postoperative gemcitabine
Description: * Preoperative mFOLFIRINOX, every 2 weeks, 8 cycles~  * Oxaliplatin IV 85 mg/m2 Day (D) 1~ * Irinotecan IV 180 mg/m2 D1~ * 5-FU continuous IV infusion 2,400 mg/m2 over 46 hours D1-2~ * Leucovorin IV 400 mg/m2 D1~* Postoperative gemcitabine, every 4 weeks, 3-6 cycles - Gemcitabine 1,000 mg/ m2 D1, 8, and 15
Study NCT01176318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdosteine
Description: capsule 300mg twice daily for 10 days
Study NCT01176318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsule, twice daily for 10 days
Study NCT04517942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EVERYbody Project
Description: Brief behavioral intervention (4 hours across two meetings)
Study NCT04517942 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video + Expressive Writing
Description: Brief video-based intervention (4 hours across two meetings)
Study NCT01005368 — intervention group
Intervention type: GENETIC
Intervention: fluorescence in situ hybridization
Study NCT01005368 — intervention group
Intervention type: GENETIC
Intervention: mutation analysis
Study NCT01005368 — intervention group
Intervention type: GENETIC
Intervention: nucleic acid sequencing
Study NCT01005368 — intervention group
Intervention type: GENETIC
Intervention: polymerase chain reaction
Study NCT01005368 — intervention group
Intervention type: GENETIC
Intervention: western blotting
Study NCT01005368 — intervention group
Intervention type: OTHER
Intervention: flow cytometry
Study NCT01005368 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study NCT01587118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjunctive asenapine
Description: participants who are not responding fully to antidepressant therapy for PTSD will receive adjunctive asenapine (flexible dosing beginning with 5 mg sublingual once per day, titrated up to 10 mg twice per day, as tolerated) for a total of 12 weeks.
Study NCT03598881 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment
Study NCT03598881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment
Study NCT00263575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN3267
Description: EN3267 will be available in 100, 200, 300, 400, 600 (two 300 ug tablets), and 800 ug (two 400 ug tablets) doses
Study NCT01328210 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood letting
Description: blood letting twice within 4 weeks. First blood removal baseline with 400ml of venous blood and second blood removal with 300-400ml according to serum ferritin levels.
Study NCT02781298 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: New Infant Cereal
Description: The infants will start the complementary feeding with the infants cereals of this study, the amount of cereal ingested will be free according to pediatricians recommendations.
Study NCT02781298 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: New Infant Cereal
Description: The infants will start the complementary feeding with the infants cereals of this study, the amount of cereal ingested will be free according to pediatricians recommendations.
Study NCT02781298 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multicereals Infant Cereal
Description: The infants will start the complementary feeding with the infants cereals of this study, the amount of cereal ingested will be free according to pediatricians recommendations.
Study NCT02781298 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multicereals Infant Cereal
Description: The infants will start the complementary feeding with the infants cereals of this study, the amount of cereal ingested will be free according to pediatricians recommendations.
Study NCT04064294 — intervention group
Intervention type: DRUG
Intervention: Intravenous Infusion
Description: Intravenous levodopa given 1.0 to 1.5 mg/kg/hr from 0930 - 1130 on a single visit day.
Study NCT03749499 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HTN Educational Video
Description: The video will educate participants in arm 2 about high BP, how it is diagnosed, and the importance of treating it to prevent secondary complications.
Study NCT03749499 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visual Echocardiogram Image Clips
Description: Visual clips of age/gender-matched echocardiograms will be used to educate and motivate patients to change their behavior and improve their BP. We have found that real time visualization of cardiac ultrasound images with active discussion of findings is a significant patient motivator and empowerment tool, and was a significant factor in the success of our previous pilot study.
Study NCT03749499 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Health and Remote BP monitoring
Description: All participants randomized to the intervention group will receive an FDA-approved HBPM kit that includes the Nokia wireless (self-inflating) BPM+ monitor and Health Mate mobile app. The app automatically launches when the patient slips on the cuff and turns on the monitor to measure his/her BP. Synced data are automatically uploaded from the mobile app to the iCardia server of our study.
Study NCT03749499 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post-Acute Care HTN Transition consultation (PACHT-c)
Description: All participants randomized to the E2 intervention will have a focused consultation with either a clinical pharmacist or an APN. During this consultation, the pharmacist/APN repeats the BP measurement; reviews the screening assessments; and reviews general principles of BP control including nutrition, exercise, and smoking cessation. BP will be managed according to the current published guidelines available at the time of funding regarding initiation of first-line antihypertensive medications. Patients with BP ≥160/100 mmHg may be started on antihypertensive medications by the provider during the consultation if appropriate.
Study NCT01530386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide will be given orally in 50 mg tablets twice a day for 7 days. The dose will increase weekly by 100 mg per day to a target dose of 300 mg per day. Once the target dose of 300 mg per day has been achieved for 9 days, a 2-day tapering of Lacosamide will occur by 100 mg per day.
Study NCT00984438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCNU Wafer
Description: Implantable during surgical resection into the tumor bed
Study NCT00984438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV every 2 weeks for up to one year
Study NCT00984438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV every 2 weeks for up to one year
Study NCT01363310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine XR
Description: Dosage form: tablets Day 1-2: 50 mg Day 3-7: 150 mg Day 8-57: either 150 or 300 mg/day (flexible)
Study NCT01363310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Dosage form: capsules Day 1-7: 10 mg Day 8-57: 10 or 20 mg/day (flexible)
Study NCT05394090 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: saliva stimulation
Description: In 50 patients with ischemic stroke, saliva was the option of a neurologopedic massage of choice
Study NCT03167177 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
Study NCT03167177 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Recombinant human anti-VEGF IgG1 monoclonal antibody
Study NCT03167177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Study NCT03167177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: (SP-4-2)-diamminedichloroplatinum(II)
Study NCT03167177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study NCT03167177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Study NCT03167177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6- pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
Study NCT03167177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: 5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
Study NCT03167177 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Recombinant human anti-PD-1 IgG4 monoclonal antibody
Study NCT03167177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3-acid ethyl esters
Description: Omega-3-acid ethyl esters
Study NCT03167177 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: radiation
Study NCT03167177 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: Recombinant human super agonist interleukin-15 (IL-15) complex
Study NCT03167177 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011
Description: Ad5 \[E1-, E2b-\]-CEA
Study NCT01801553 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual medical care
Study NCT01801553 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual medical care
Study NCT03167177 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051
Description: Ad5 \[E1-, E2b-\]-Brachyury
Study NCT03167177 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061
Description: Ad5 \[E1-, E2b-\]-MUC1
Study NCT03167177 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6207
Description: Heat-killed S. cerevisiae yeast expressing CEA
Study NCT03167177 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6301
Description: Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein
Study NCT03167177 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK
Description: NK-92 \[CD16.158V, ER IL-2\] (high-affinity activated Natural Killer cells)